Hemophilia | ATHN CV

Real-world Use of Prophylaxis in People with Non-Severe Hemophilia in the United States: Insights from the ATHN Transcends Study – Hemophilia Natural History Arm – Winner of ASH Abstract Achievement Award!

Author(s):

Fernando F. Corrales-Medina, Nana Ama Afari-Dwamena, Amanda Blair, Shannon L. Carpenter, Clay T. Cohen, Maissaa Janbain, Janice M. Staber, Jonathan Schwartz, Michael Recht, Tammuella Chrisentery-Singleton

Publication:

ASH 2025 Poster

Date:

December 9, 2025

Topics:

Hemophilia, Prophylaxis

Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study

Author(s):

Tyler W. Buckner, Shannon L. Carpenter, Nabil Daoud, Christine L. Kempton, Lucy Lee, Lynn Malec, Thomas W. McLean, Paul Morton, Carrie O’Neill, Janice M. Staber, Michael Wang, Stacy E. Croteau, Michael Recht

Publication:

Haemophilia

Date:

November 11, 2025

Topics:

Haemophilia

Effectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset

Author(s):

Martin Chandler, Thomas Moulton, Lena Charafi, Jessica Charlet, Michael Recht.

Publication:

European Journal of Haematology

Date:

November 18, 2024

Topics:

Hemophilia A, prophylaxis, ATHNdataset

Application of Artificial Intelligence and Machine Learning Was Not Able to Reliably Predict Poor Outcomes in People with Hemophilia

Author(s):

Jianzhong Hu, Lu Chen, Bob Rogers, Martin Chandler, Jarren Santos

Publication:

Cureus

Date:

August 13, 2024

Topics:

Hemophilia

IX-TEND: A Phase IV Observational, Long-Term Follow-Up Study on the Safety and Efficacy of Etranacogene Dezaparvovec in Patients with Hemophilia B

Author(s):

Andreas Tiede, Blanca Salazar, Sean Gill, Paul E. Monahan, Tammuella Chrisentery-Singleton

Publication:

ISTH Congress 2024

Date:

June 22-26, 2024

Topics:

etranacogene dezaparvovec, hemophilia B, ATHN Transcends